



(54) Title: USE OF TETRAHYDROCARBAZONE DERIVATIVES AS SHT RECEPTOR AGONISTS

## ABSTRACT

## (STATE WATER

Use of a compound of general formula (I), wherein R<sup>1</sup> represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy,  $C_{1.6}$ alkyl,  $C_{1.6}$ alkoxy, aryl $C_{1.6}$ alkoxy,  $-CO_2$ R<sup>4</sup>,  $-(CH_2)_n$ CN.  $-(CH_2)_n$ CONR<sup>5</sup>R<sup>6</sup>,  $-(CH_2)_n$ SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>,  $C_{1.6}$ alkylsulphonylamino(CH<sub>2</sub>)<sub>n</sub>; R<sup>4</sup> represents hydrogen,  $C_{1.6}$ alkyl or aryl $C_{1.6}$ alkyl; R<sup>5</sup> and R<sup>6</sup> each independently represent hydrogen or  $C_{1.6}$ alkyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R<sup>2</sup> and R<sup>3</sup> each independently represent hydrogen,  $C_{1.6}$ alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolldino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT<sub>1</sub>-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.